AHL
BCRX icon

Abel Hall LLC’s BioCryst Pharmaceuticals BCRX Stock Holding History

Abel Hall LLC’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Buy
+18,994
New +$172K 0.03% 755
2026
Q1 		– Sell
-24,898
Closed -$194K – 828
2025
Q4 		$194K Buy
+24,898
New +$180K 0.05% 554

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Abel Hall LLC's BCRX Position: Q2 2026 in Review

Abel Hall LLC opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 18,994 shares worth $190K. The stake represents 0.03% of the portfolio and ranks #755 among its holdings. This is a return to the name: Abel Hall LLC previously reported a position in BCRX as recently as Q4 2025.

Abel Hall LLC first reported a position in BCRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $194K in Q4 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Abel Hall LLC held 18,994 shares of BioCryst Pharmaceuticals worth $190K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Abel Hall LLC position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.03% of Abel Hall LLC's portfolio in Q2 2026, its #755 holding.
  • Abel Hall LLC first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's BioCryst Pharmaceuticals position peaked at $194K in Q4 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.